Close Menu

Swift Biosciences

The workflow combines Swift's Adaptase technology and RNA library kits with Arbor's myBaits technology for hybridization-based target enrichment of the virus.

LGC will be Swift's worldwide partner for amplicon-based targeted sequencing assays for genotyping AgBio samples, including crop species and animals. 

Under the agreement, the companies plan to make Swift's library preparation kits compatible with MGI's DNBSEQ sequencers.

The two companies hope to provide translational researchers a faster, more comprehensive option for the design and validation of Accel-Amplicon panels.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.